Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | MRD-guided therapy in multiple myeloma

Benjamin Derman • 1 Jun 2022
EHA 2022
Multiple Myeloma

Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease (MRD)-guided therapy in multiple myeloma, highlighting key clinical trials using MRD to guide discontinuation of maintenance therapy and explaining the importance of better understanding how to both escalate and de-escalate therapy in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria for advisory board fees from Janssen, Sanofi, and COTA healthcare.

More from Benjamin Derman

4:26
The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman • 1 Dec 2023
3:43
MRD-guided treatment cessation in multiple myeloma
Benjamin Derman • 1 Dec 2023
9:57
Quadruplet therapies for treating MM: the current evidence and the findings of a Phase II trial
Benjamin Derman • 1 Dec 2023
5:25
MRD by mass spectrometry in PB and NGS in BM in patients with multiple myeloma treated with Dara-KRd
Benjamin Derman • 1 Jun 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals